The arrival of biosimilar adalimumab in European markets has been cause for enthusiasm among those seeking greater patient access and lower costs for the treatment of rheumatoid arthritis (RA). However, AbbVie (maker of the reference adalimumab, Humira) has revealed that its oral Janus kinase inhibitor, upadacitinib, outperformed both placebo and adalimumab in a phase 3 study.
The arrival of biosimilar adalimumab in European markets has been cause for enthusiasm among those seeking greater patient access and lower costs for the treatment of rheumatoid arthritis (RA). However, AbbVie (maker of the reference adalimumab, Humira) has revealed that its oral Janus kinase (JAK) inhibitor, upadacitinib, outperformed both placebo and adalimumab in a phase 3 study.
The results of the SELECT-COMPARE trial, which AbbVie first announced in topline in April 2018, were presented during the American College of Rheumatology (ACR)’s annual meeting, held in Chicago, Illinois, October 19-24, 2018.
In the trial, 1629 patients with active RA despite methotrexate treatment were randomized 2:2:1 to receive 15 mg of upadacitinib daily, placebo, or 40 mg of adalimumab every other week, all while continuing methotrexate. The study’s primary end points were noninferiority and superiority of upadacitinib versus adalimumab at week 12 and radiographic inhibition for upadacitinib versus placebo at week 26.
In total, 91% of patients completed the full 26 weeks. At week 12, 70.5% of those receiving upadacitinib and 36.4% of those receiving placebo achieved ACR criteria for 20% improvement (ACR20); 28.7% and 6.1%, respectively, had a disease activity score in a count of 28 joints plus C-reactive protein (DAS28-CRP) of under 2.6. At week 26, more patients receiving upadacitinib had no radiographic progression than patients receiving placebo (83.5% vs 76.0%).
Upadacitinib also demonstrated superiority versus adalimumab at week 12 for ACR50 (45.2% vs 29.1%) and for DAS28-CRP of 3.2 or less (45.0% vs 28.7%). Furthermore, upadacitinib was superior in terms of reduction of pain and improvement in quality of life as measured by the Health Assessment Questionnaire Disability Index.
The proportion of patients with adverse events (AEs) was higher for those given upadacitinib than those given placebo, but similar to those given adalimumab. Notably, thromboembolic events were similar across the 3 arms; 6 venous thromboembolic events occurred, 1 in the placebo arm, 2 in the upadacitinib arm, and 3 in the adalimumab arm. In a previous phase 3 study in the same clinical program, SELECT-MONOTHERAPY, some concerns arose about the safety of the drug; 1 patient taking the study drug died of a hemorrhagic stroke, caused by a ruptured aneurysm.
The positive data from this phase 3 trial may to support AbbVie in its effort to find a fresh foothold in the RA market as 4 EU competitors to Humira begin to sell their products, and as sales will begin for adalimumab biosimilars in the United States in 2023.
Reference
Fleischmann R, Pangan AL, Mysler E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Presented at: American College of Rheumatology 2018 Meeting; October 19-24, 2018; Chicago, Illinois. Abstract 890. https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-study-comparing-upadacitinib-to-placebo-and-to-adalimumab-in-patients-with-active-rheumatoid-arthritis-with-inadequate-response-to-methotrexate/.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).